Tema Etfs LLC Makes New $1.73 Million Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Tema Etfs LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 148,167 shares of the company's stock, valued at approximately $1,728,000. Tema Etfs LLC owned about 0.15% of Intellia Therapeutics at the end of the most recent quarter.

Several other large investors have also modified their holdings of NTLA. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of Intellia Therapeutics by 125.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock valued at $1,411,000 after acquiring an additional 67,276 shares during the period. Avanza Fonder AB purchased a new stake in Intellia Therapeutics in the 4th quarter valued at $421,000. Barclays PLC raised its position in Intellia Therapeutics by 17.7% in the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock valued at $6,017,000 after purchasing an additional 44,022 shares during the last quarter. ARK Investment Management LLC boosted its stake in Intellia Therapeutics by 2.3% during the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after purchasing an additional 280,946 shares during the period. Finally, SG Americas Securities LLC grew its position in Intellia Therapeutics by 85.7% during the 4th quarter. SG Americas Securities LLC now owns 44,838 shares of the company's stock worth $523,000 after purchasing an additional 20,694 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NTLA shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a report on Friday, February 28th. Citigroup reduced their price objective on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. Morgan Stanley downgraded Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $56.00 to $11.00 in a research note on Monday, January 27th. Wolfe Research upgraded Intellia Therapeutics from a "peer perform" rating to an "outperform" rating and set a $21.00 price target for the company in a research note on Monday, April 21st. Finally, Chardan Capital reaffirmed a "buy" rating and set a $68.00 price target on shares of Intellia Therapeutics in a report on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Intellia Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $36.90.

Intellia Therapeutics Stock Performance

NTLA traded down $0.47 on Wednesday, hitting $9.20. 4,182,130 shares of the company were exchanged, compared to its average volume of 2,552,577. The business's fifty day moving average is $7.99 and its 200 day moving average is $10.67. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.18. The firm has a market capitalization of $952.96 million, a P/E ratio of -1.69 and a beta of 2.33.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. The firm had revenue of $16.63 million during the quarter, compared to analyst estimates of $11.39 million. The business's revenue was down 42.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.12) EPS. Analysts forecast that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.